Your privacy, your choice

We use essential cookies to make sure the site can function. We also use optional cookies for advertising, personalisation of content, usage analysis, and social media.

By accepting optional cookies, you consent to the processing of your personal data - including transfers to third parties. Some third parties are outside of the European Economic Area, with varying standards of data protection.

See our privacy policy for more information on the use of your personal data.

for further information and to change your choices.

You are viewing the site in preview mode

Skip to main content
Fig. 2 | Journal of Translational Medicine

Fig. 2

From: Overview of preclinical and phase II clinical studies on Pegmolesatide’s long-term erythropoiesis stimulating effect via EPOR-mediated signal transduction

Fig. 2

Pegmolesatide has a stronger ability to maintain UT-7 cell proliferation than ESPO 3000 at matched biological doses. A and B Effect of drugs on the proliferation of UT-7 cells. UT-7 cells in logarithmic growth phase were adjusted to 1.2 × 104cells/mL with complete medium without EPO. Cells were treated with drugs (Pegmolesatide or ESPO3000 or peptide dimer) for 0, 1, 2, 3, 4, 5, 7, 8, and 9 days. C The effect of drugs on cell survival. After treating cells with drugs for 7 days, centrifuge and discard the supernatant, adjust the cell density to 1.0 × 105cells/mL with complete medium without EPO. Continue to culture the cells for 0, 1, 2, 3, 4, and 7 days. Use Cell Titer-Glo® 2.0 Cell Viability Assay to detect cell luminescence signals. The magnitude of the signal value is proportional to the number of viable cells. Data are presented as Mean ± SD. N = 3 per time point

Back to article page